Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi‐centre study comparing real‐time polymerase chain reaction and multicolour flow cytometry
Open Access
- 20 January 2011
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 152 (6), 743-753
- https://doi.org/10.1111/j.1365-2141.2010.08456.x
Abstract
Minimal residual disease (MRD) assessment is a powerful prognostic factor for determining the risk of relapse in childhood acute lymphoblastic leukaemia (ALL). In this Swedish multi‐centre study of childhood ALL diagnosed between 2002 and 2006, the MRD levels were analysed in 726 follow‐up samples in 228 children using real‐time quantitative polymerase chain reaction (RQ‐PCR) of rearranged immunoglobulin/T‐cell receptor genes and multicolour flow cytometry (FCM). Using an MRD threshold of 0·1%, which was the sensitivity level reached in all analyses, the concordance between RQ‐PCR and FCM MRD values at day 29 was 84%. In B‐cell precursor ALL, an MRD level of ≥0·1% at day 29 predicted a higher risk of bone marrow relapse (BMR) with both methods, although FCM was a better discriminator. However, considering the higher median MRD values achieved with RQ‐PCR, a higher MRD cut‐off (≥0·2%) improved the predictive capacity of RQ‐PCR. In T‐ALL, RQ‐PCR was notably superior to FCM in predicting risk of BMR. That notwithstanding, MRD levels of ≥0·1%, detected by either method at day 29, could not predict isolated extramedullary relapse. In conclusion, the concordance between RQ‐PCR and FCM was high and hence both methods are valuable clinical tools for identifying childhood ALL cases with increased risk of BMR.This publication has 43 references indexed in Scilit:
- Quality Control of Flow Cytometry Data Analysis for Evaluation of Minimal Residual Disease in Bone Marrow From Acute Leukemia Patients During TreatmentJournal of Pediatric Hematology/Oncology, 2009
- Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemiaBritish Journal of Haematology, 2008
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyBlood, 2008
- Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemiaLeukemia, 2008
- The Incidence Peaks of the Childhood Acute Leukemias Reflect Specific Cytogenetic AberrationsJournal of Pediatric Hematology/Oncology, 2006
- Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real‐time PCRBritish Journal of Haematology, 2005
- Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemiaLeukemia, 2003
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998
- Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 1998
- Immunoglobulin gene ‘fingerprinting’: an approach to analysis of B lymphoid clonality in lymphoproliferative disordersBritish Journal of Haematology, 1991